Variable | Recurrence-free survival | ||
---|---|---|---|
HR | 95% CI | p | |
Model A | |||
 Primary tumor (T) (III/IV vs I/II) | 2.058 | 1.364–3.104 | 0.001 |
 Lymph nodes metastasis (N) (Yes vs No) | 1.617 | 1.083–2.413 | 0.019 |
 TNM Stage (III/IV vs I/II) | 1.107 | 0.654–1.873 | 0.705 |
 EGFR (High vs Low) | 1.542 | 1.131–2.103 | 0.006 |
Model B | |||
 Primary tumor (T) (III/IV vs I/II) | 2.000 | 1.312–3.047 | 0.001 |
 Lymph nodes metastasis (N) (Yes vs No) | 1.459 | 0.963–2.211 | 0.075 |
 TNM Stage (III/IV vs I/II) | 1.158 | 0.668–2.009 | 0.601 |
 HER4 (High vs Low) | 1.388 | 1.011–1.906 | 0.042 |
Model C | |||
 Primary tumor (T) (III/IV vs I/II) | 1.977 | 1.296–3.017 | 0.002 |
 Lymph nodes metastasis (N) (Yes vs No) | 1.467 | 0.967–2.225 | 0.071 |
 TNM Stage (III/IV vs I/II) | 1.242 | 0.712–2.168 | 0.445 |
 EphA3 (High vs Low) | 1.469 | 1.091–1.977 | 0.011 |
Model D | |||
 Primary tumor (T) (III/IV vs I/II) | 1.918 | 1.255–2.931 | 0.003 |
 Lymph nodes metastasis (N) (Yes vs No) | 1.480 | 0.979–2.240 | 0.063 |
 TNM Stage (III/IV vs I/II) | 1.193 | 0.686–2.073 | 0.531 |
 Protein panela (2–3 markers high vs Othersb) | 1.528 | 1.116–2.091 | 0.008 |
Model E | |||
 Primary tumor (T) (III/IV vs I/II) | 3.275 | 1.710–6.273 | 3.5 × 10−4 |
 Lymph nodes metastasis (N) (Yes vs No) | 1.749 | 1.017–3.009 | 0.043 |
 TNM Stage (III/IV vs I/II) | 0.660 | 0.292–1.496 | 0.320 |
 Combined of protein panel and CA19–9 level (2–3 markers high and CA19–9 high vs Othersc) | 2.080 | 1.270–3.405 | 0.004 |